Condition: HNSCC · ESCC · Esophageal Adenocarcinoma · Sponsor: Normunity AccelCo, Inc.
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
This description comes directly from the study's public registry record.
Judy Schnyder, MBA · 215-593-7119 · judy.schnyder@normunity.com
Always discuss trial participation with your own doctor first.
| Normunity Investigational Site | Denver, Colorado, United States | Recruiting |
| Normunity Investigational Site | New Haven, Connecticut, United States | Recruiting |
| Normunity Investigational Site | Minneapolis, Minnesota, United States | Recruiting |
| Normunity Investigational Site | Maumee, Ohio, United States | Recruiting |
| Normunity Investigational Site | Philadelphia, Pennsylvania, United States | Recruiting |
| Normunity Investigational Site | Nashville, Tennessee, United States | Recruiting |
| Normunity Investigational Site | Dallas, Texas, United States | Recruiting |
| Normunity Investigational Site | San Antonio, Texas, United States | Recruiting |
| Normunity Investigational Site | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07182149